Hostname: page-component-7479d7b7d-8zxtt Total loading time: 0 Render date: 2024-07-13T16:06:54.055Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessment of Executive Function in Clinical Trials

Published online by Cambridge University Press:  10 January 2005

Raija Ylikoski  and
Tuomo Hänninen
Raija Ylikoski
Affiliation:
Helsinki University Central Hospital, Department of Neurology, HUS, Finland
Tuomo Hänninen
Affiliation:
Department of Neurology, Kuopio University Hospital, Kuopio, Finland
Get access Rights & Permissions [Opens in a new window]

Abstract

Cerebrovascular disease and stroke are related to high risk of cognitive impairment. One of the main neuropsychological features in vascular cognitive impairment and vascular dementia is executive dysfunction. Definition of the essential subcomponents and concepts of executive function is important before determining the methodology in clinical trials. The scientific research and new methods on this topic are rapidly growing. We present some most commonly used neuropsychological tests and discuss the methodological aspects in light of clinical trials.

Keywords

Executive functioncognitionneuropsychology
Type
TRIAL DESIGNS: SYMPTOMATIC
Information
International Psychogeriatrics , Volume 15 , Issue S1 , July 2003 , pp. 219 - 224
Copyright
© 2003 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)